SCHEMBL2401601

SCHEMBL2401601

CN(C1CCN1C1=CC(=O)c2nc(-c3cc(F)ccc3F)oc2C1=O)C1CCN1C1=CC(=O)c2nc(-c3cc(F)ccc3F)oc2C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.55
CDC25B P30305 1/20 0.55
CDC25C P30307 1/20 0.55
USP1 O94782 4/20 0.33
USP8 P40818 3/20 0.33
OTUB1 Q96FW1 3/20 0.33
USP2 O75604 2/20 0.33
USP36 Q9P275 2/20 0.33
USP19 O94966 1/20 0.32
UCHL3 P15374 1/20 0.32
SLC9A1 P19634 1/20 0.32
PTPN1 P18031 1/20 0.32
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
PKM P14618 1/20 0.31
CYP11B2 P19099 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404414 0.86 USP1 (0.44) CDC25ACDC25BCDC25CUSP1USP19
SCHEMBL2403259 0.79 TP53 (0.36) USP2
SCHEMBL2398532 0.79 MEN1 (0.33) CDC25ACDC25BCDC25CUSP1USP19
SCHEMBL2401248 0.77 NPSR1 (0.35) CDC25ACDC25BCDC25CUSP1USP2
SCHEMBL2399059 0.75 CDC25A (0.56) CDC25ACDC25BCDC25CUSP1USP8
SCHEMBL2402102 0.72 CDC25A (0.60) CDC25ACDC25BCDC25CUSP1USP19
SCHEMBL1917955 0.71 CDC25A (1.00) CDC25ACDC25BCDC25CUSP1USP19
SCHEMBL5259655 0.70 CDC25A (0.68) CDC25ACDC25BCDC25CUSP1USP19
SCHEMBL2399058 0.70 CDC25A (0.62) CDC25ACDC25BCDC25CUSP1USP19
SCHEMBL1917951 0.70 CDC25A (0.70) CDC25ACDC25BCDC25CPTPN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed
EP-1831209-A2 CDC25 PHOSPHATASE INHIBITORS Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) 2007-09-12 EP disclosed
WO-2006067311-A2 CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.